Literature DB >> 15452266

Thogoto virus lacking interferon-antagonistic protein ML is strongly attenuated in newborn Mx1-positive but not Mx1-negative mice.

Andreas Pichlmair1, Johanna Buse, Stephanie Jennings, Otto Haller, Georg Kochs, Peter Staeheli.   

Abstract

The Thogoto virus ML protein suppresses interferon synthesis in infected cells. Nevertheless, a virus mutant lacking ML remained highly pathogenic in standard laboratory mice. It was strongly attenuated, however, in mice carrying the interferon-responsive Mx1 gene found in wild mice, demonstrating that enhanced interferon synthesis is protective only if appropriate antiviral effector molecules are present. Our study shows that the virulence-enhancing effects of some viral interferon antagonists may escape detection in conventional animal models.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15452266      PMCID: PMC521850          DOI: 10.1128/JVI.78.20.11422-11424.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  17 in total

1.  A recombinant influenza A virus expressing an RNA-binding-defective NS1 protein induces high levels of beta interferon and is attenuated in mice.

Authors:  Nicola R Donelan; Christopher F Basler; Adolfo García-Sastre
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

Review 2.  Intracellular warfare between human influenza viruses and human cells: the roles of the viral NS1 protein.

Authors:  Robert M Krug; Weiming Yuan; Diana L Noah; Anita Ghate Latham
Journal:  Virology       Date:  2003-05-10       Impact factor: 3.616

3.  Influenza virus-susceptible mice carry Mx genes with a large deletion or a nonsense mutation.

Authors:  P Staeheli; R Grob; E Meier; J G Sutcliffe; O Haller
Journal:  Mol Cell Biol       Date:  1988-10       Impact factor: 4.272

4.  Replication-competent rhabdoviruses with human immunodeficiency virus type 1 coats and green fluorescent protein: entry by a pH-independent pathway.

Authors:  E Boritz; J Gerlach; J E Johnson; J K Rose
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

5.  Rescue of recombinant Thogoto virus from cloned cDNA.

Authors:  E Wagner; O G Engelhardt; S Gruber; O Haller; G Kochs
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

6.  Antiviral activity of a novel recombinant human interferon-alpha B/D hybrid.

Authors:  J D Gangemi; J Lazdins; F M Dietrich; A Matter; B Poncioni; H K Hochkeppel
Journal:  J Interferon Res       Date:  1989-04

7.  Novel gene product of Thogoto virus segment 6 codes for an interferon antagonist.

Authors:  Kathrin Hagmaier; Stephanie Jennings; Johanna Buse; Friedemann Weber; Georg Kochs
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

8.  Imbalanced cytokine secretion in newborns.

Authors:  Anna Kotiranta-Ainamo; Jukka Rautonen; Nina Rautonen
Journal:  Biol Neonate       Date:  2003-11-19

9.  Interferon induces a unique protein in mouse cells bearing a gene for resistance to influenza virus.

Authors:  M A Horisberger; P Staeheli; O Haller
Journal:  Proc Natl Acad Sci U S A       Date:  1983-04       Impact factor: 11.205

10.  Virus-specific interferon action. Protection of newborn Mx carriers against lethal infection with influenza virus.

Authors:  O Haller; H Arnheiter; I Gresser; J Lindenmann
Journal:  J Exp Med       Date:  1981-07-01       Impact factor: 14.307

View more
  12 in total

1.  IFN-lambda determines the intestinal epithelial antiviral host defense.

Authors:  Johanna Pott; Tanel Mahlakõiv; Markus Mordstein; Claudia U Duerr; Thomas Michiels; Silvia Stockinger; Peter Staeheli; Mathias W Hornef
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-25       Impact factor: 11.205

Review 2.  Mx proteins: antiviral gatekeepers that restrain the uninvited.

Authors:  Judith Verhelst; Paco Hulpiau; Xavier Saelens
Journal:  Microbiol Mol Biol Rev       Date:  2013-12       Impact factor: 11.056

Review 3.  An Overview of Animal Models for Arthropod-Borne Viruses.

Authors:  Erin S Reynolds; Charles E Hart; Meghan E Hermance; Douglas L Brining; Saravanan Thangamani
Journal:  Comp Med       Date:  2017-06-01       Impact factor: 0.982

4.  Thogoto virus infection induces sustained type I interferon responses that depend on RIG-I-like helicase signaling of conventional dendritic cells.

Authors:  Georg Kochs; Stefanie Bauer; Carola Vogt; Theresa Frenz; Jürg Tschopp; Ulrich Kalinke; Zoe Waibler
Journal:  J Virol       Date:  2010-09-22       Impact factor: 5.103

5.  Innate immune responses in NF-kappaB-repressing factor-deficient mice.

Authors:  Natali Froese; Michael Schwarzer; Ina Niedick; Ursula Frischmann; Mario Köster; Andrea Kröger; Peter P Mueller; Mahtab Nourbakhsh; Bastian Pasche; Jörg Reimann; Peter Staeheli; Hansjörg Hauser
Journal:  Mol Cell Biol       Date:  2006-01       Impact factor: 4.272

6.  Response of Three Different Viruses to Interferon Priming and Dithiothreitol Treatment of Avian Cells.

Authors:  Irene Lostalé-Seijo; José Martínez-Costas; Javier Benavente
Journal:  J Virol       Date:  2016-08-26       Impact factor: 5.103

7.  The interferon antagonist ML protein of thogoto virus targets general transcription factor IIB.

Authors:  Carola Vogt; Ellen Preuss; Daniel Mayer; Friedemann Weber; Martin Schwemmle; Georg Kochs
Journal:  J Virol       Date:  2008-09-03       Impact factor: 5.103

8.  Influenza Virus Susceptibility of Wild-Derived CAST/EiJ Mice Results from Two Amino Acid Changes in the MX1 Restriction Factor.

Authors:  Cindy Nürnberger; Vanessa Zimmermann; Melanie Gerhardt; Peter Staeheli
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

9.  Viral targeting of TFIIB impairs de novo polymerase II recruitment and affects antiviral immunity.

Authors:  Darya A Haas; Arno Meiler; Katharina Geiger; Carola Vogt; Ellen Preuss; Georg Kochs; Andreas Pichlmair
Journal:  PLoS Pathog       Date:  2018-04-30       Impact factor: 6.823

Review 10.  Interferon, Mx, and viral countermeasures.

Authors:  Otto Haller; Georg Kochs; Friedemann Weber
Journal:  Cytokine Growth Factor Rev       Date:  2007-08-01       Impact factor: 7.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.